Warning: Invalid argument supplied for foreach() in /home/globaldi/public_html/modules/mod_banners/tmpl/default.php on line 9
 

Akela Pharma to cut costs to sustain long-term viability of the company (CNW Group via Yahoo! Finance) PDF Print

Akela Pharma Inc. , a drug development company focused on developing an inhaled fentanyl product for breakthrough cancer pain and a growth hormone releasing hormone for chronic renal disease, today announced it will be implementing measures to cut costs in order to preserve cash for its continued operations.

read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.